Demonstrating the effectiveness of a groundbreaking, real-time cancer assessment
Chicago, IL – April 11, 2025 — NovaScan, a leader in point-of-care cancer detection and treatment technologies, is pleased to announce that its MarginScan™ device will be featured in a poster presentation at the Wisconsin Dermatology Society (WDS) Spring Meeting on April 26, 2025.
The poster, titled “Rapid Margin Assessment for Non-Melanoma Skin Cancer During Mohs Micrographic Surgery,” will highlight the clinical performance of MarginScan in real-time surgical margin detection. The data demonstrate the device’s ability to improve surgical efficiency and accuracy, helping dermatologic surgeons better identify cancerous tissue in the margin during Mohs procedures.
“MarginScan can be transformative for skin cancer treatment,” noted Dr Manish Gharia, board-certified Mohs surgeon and principal investigator for this study. “It can be an extremely valuable tool for Mohs Surgeons and General Dermatologists to plan better patient schedules and improve their experience and outcomes.”
“We are excited to share the progress we’ve made with MarginScan,” said Donato Ceres, NovaScan CSO. “These clinical results reflect our ongoing commitment to developing technologies that support more effective and precise cancer treatments.”
“The MarginScan clinical data demonstrates a new achievement in the sensitivity and specificity of real-time cancer assessment at the point of care,” added NovaScan CEO Craig Davis. “It benefits clinicians and patients alike.”
MarginScan is a proprietary platform device that combines NovaScan’s bioimpedance technology with machine learning to assess the margins of skin excisions in real time, offering surgeons immediate feedback during skin cancer surgeries. Its application in skin cancer surgery aims to enhance patient outcomes by providing real-time feedback on the presence and location of cancer in the margin of skin excisions.
The WDS Spring Meeting brings together leading dermatologists and researchers to discuss advances in the field. NovaScan is proud to be contributing to the conversation with data that could help shape the future of skin cancer treatment.
For more information about NovaScan and MarginScan, please visit www.novascaninc.com.